BioWorld / Analysis and data insight / Regulatory / U.S. / FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Oct. 30, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for October 30, 2024.
By the numbers: US leads charge of cell and gene therapies
BioWorld
U.S. biotechs and regulators ushered in the era of gene therapy in 2023, experts at Bio Japan said, but medical reform is needed to pave the way for the “year of...
After delays, Abbvie wins FDA approval for Parkinson’s treatment
BioWorld
With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating...
Nanocube’s nanorobots to revolutionize cancer diagnosis, treatment
BioWorld MedTech
Nanocube Health Ltd. is developing accessible, low-cost nanorobots that could revolutionize diagnosis and treatment of hard-to-diagnose cancers, with pancreatic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe